Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 22;13(3):257. doi: 10.1038/s41419-022-04707-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — A UPF1 expression levels in EC tissues (N = 546) and normal tissues (n = 33) in the TCGA cohort. B UPF1 expression levels in EC tissues (n = 58) compared to normal tissues (n = 32) detected using qRT-PCR. Data are presented as the means ± SEM, **P < 0.01. C UPF1 expression levels in EC tissues (n = 58) compared to normal tissues (n = 32) detected using western blotting. Data are presented as the means ± SEM, ***P < 0.001. D UPF1 expression levels in patients with different (D-i) tumor stages and (D-ii) myometrial invasion in EC tissues (n = 58) compared to normal tissues (n = 32). Data are presented as the means ± SEM, **P < 0.01. E Flow cytometry analysis of CD133⁺/CD44⁺ cells sorted from the 1st and 3rd ECSCs. F The expression of UPF1, SOX2, OCT4, and NANOG in ECCs, non-ECSCs, and ECSCs detected using western blotting. The results are presented as the ratio of the integrated density values of UPF1, SOX2, OCT4, and NANOG versus Tubulin. The graphs represent the alteration in relation to ECCs (protein of interest/Tubulin equal to 1). Data are presented as the means ± SEM (n = 3, each group), *P < 0.05 vs. ECCs group, #P < 0.05 vs. non-ECSCs group. G The expression of UPF1, SOX2, OCT4, and NANOG in CD133⁻/CD44⁻, CD133⁻/CD44⁺, CD133⁺/CD44⁻, and CD133⁺/CD44⁺ cells detected using western blotting. The results are presented as the ratio of the integrated density values of UPF1, SOX2, OCT4, and NANOG versus Tubulin and the graphs represent the alteration in relation to the CD44−/CD133− cells (protein of interest/Tubulin equal to 1). Data are presented as the means ± SEM (n = 3, each group), *P < 0.05 vs. CD133⁻/CD44⁻ group, #P < 0.05 vs. CD133⁻/CD44⁺ group, △P < 0.05 vs. CD133^+/CD44⁻ group. H Effect of UPF1 overexpression or knockdown on SOX2, OCT4, and NANOG expression assessed using western blotting. The results are presented as the ratio of the integrated density values of UPF1, SOX2, OCT4, and NANOG versus Tubulin. The graphs represent the alteration in the oe-UPF1 group and the sh-UPF1 group relative to their respective control groups (protein of interest/Tubulin equal to 1). Data are presented as the means ± SEM, *P < 0.05 vs. oe-NC group, #P < 0.05 vs. sh-NC group.